Close menu




April 24th, 2020 | 07:36 CEST

BioNTech, Gilead, Memphasys - in the spotlight of investors overnight

  • Medical
Photo credits: pixabay.com

There are topics and products that are the focus of general interest overnight. Often these are needs or problems that require a time-critical solution. The current situation surrounding the spread of the Corona Virus COVID-19 has brought numerous companies into the focus of investors in recent weeks. The backgrounds are of a very different nature. On the one hand, there are manufacturers of masks, disinfectants or respiratory equipment, as well as medical companies that may have an active ingredient for the prevention or therapy of the Corona Virus on offer. But there are also topics that are beyond the general interest and represent a huge market.

time to read: 1 minutes | Author: Mario Hose
ISIN: AU000000MEM5 , US09075V1026 , US3755581036

Table of contents:


    Growing billion dollar market

    The desire of couples to have children tends to occur increasingly later in modern society. Often professional or economic reasons are in the foreground before the family picture is rounded off with their own children. However, the chances of a successful natural pregnancy decrease with increasing age. Often couples with increasing frustration then consult appropriate experts to deal with the subject of artificial insemination.

    Solution increases chances of success

    The Australian company Memphasys has developed a product called FELIX, which separates the high-quality sperm from the man's seminal fluid and thus increases the chances of success of artificial insemination. The advantage of FELIX is that the process only takes a few minutes and the costs of treatment can be reduced. The product is to be launched in several countries in the second half of 2020. The market for artificial insemination is growing steadily and any solution that statistically increases the chances of a successful pregnancy will be in high demand.

    Memphasys shares are traded in Australia and Germany and at a price of AUD 0.048 the company has a market capitalization of AUD 36 million. Further details of the FELIX launch should increase interest in Memphasys. Introduction at the right time could be worthwhile. Further information is available in the following video interview with Executive Chairman Alison Coutts: youtu.be/kHA-UhbeZH8

    Success and failure

    BioNTech from Germany is currently working with Pfizer on the search for a vaccine against COVID-19. The news that tests are now being carried out on 200 people in order to obtain marketing authorisation if successful, has boosted the company's share price. The valuation of BioNTech has now risen to over EUR 10 billion. However, should the success fail to materialise, the disappointment is likely to be great.

    A report on Gilead Science that the drug Remdesiver did not achieve the desired success in tests in connection with the treatment of Corona patients has caused the share price to fall and the value of the company has slid back below the USD 100 billion mark. It seems that the pandemic issue will be with us for some time to come.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Nico Popp on December 9th, 2020 | 14:16 CET

    Valeo Pharma, CureVac, Moderna, Sartorius: high-flyers or latecomers?

    • Medical

    The pandemic continues to spread: Germany is now facing a complete lockdown. Meanwhile, there is good news from the vaccine and drug manufacturers. There are several vaccines available, and from 2021 onwards, vaccination programs are to be implemented rapidly in all industrialized countries. Nevertheless, question marks remain: How long a vaccination will protect a person remains to be seen. For this reason, drugs and other measures to treat patients successfully remain essential. One of these drugs has just received approval from the Canadian regulatory authorities.

    Read

    Commented by Mario Hose on May 5th, 2020 | 08:33 CEST

    Evotec, Medigene, Memphasys - the right investment timing

    • Medical

    The health sector has been in the focus of investors not only since the outbreak of the corona pandemic. The pursuit of a healthy and long life is the motivation for research and development around the globe. In addition to Europe and the USA, Australia as a continent is also a location for ideas and innovations. Investors usually always ask the same questions. How expensive and how long does it take to develop the drug or solution and how big is the market. The bigger the problem or need to be treated, the more lucrative it is.

    Read

    Commented by Mario Hose on March 4th, 2020 | 07:27 CET

    Medigene, Memphasys, Qiagen - which stocks belong in the portfolio?

    • Medical

    In times of price fluctuations, so-called 'buy on dips' strategy can be an effective method of achieving a favorable entry price for listed companies. Global trends as a framework can be decisive for a successful investment decision. For a modern society, the healthcare sector has become a particularly important sector. In addition to the desire for a long life with health and care, there is also an increasing demand for products and therapies that can fulfil couples' desire to have children. There is a broad spectrum and as an investor it is worth taking a look at the companies.

    Read